Sara Bonstein
CIK 1604019 · Chief Financial Officer · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.30M
Companies
6
Total Filings
129
Lifetime Open-Market Net
-$44.39M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | Director | — | $9.18 | — | $0 | 5 | 2026-06-12 |
| INSM | Chief Financial Officer | 69,082 | $134.61 | $9.30M | -$44.19M | 33 | 2026-06-05 |
| scPharmaceuticals Inc. (SCPH) Delisted | Director | — | $5.67 | — | $0 | 7 | 2025-10-07 |
| ONCOSEC MEDICAL Inc (ONCS) Delisted | CFO/COO | 1,881 | $0.28 | $521 | -$5.0K | 8 | 2020-01-21 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Chief Financial Officer | 226,670 | — | — | -$110.7K | 21 | 2018-04-03 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Financial Officer | 81,577 | — | — | -$83.9K | 32 | 2016-10-04 |
Recent Filings · Page 10 of 13
129 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-04-03 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | +194 | $1.6K | EDGAR |
| 2017-03-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | +202 | $1.8K | EDGAR |
| 2017-02-02 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | +194 | $1.7K | EDGAR |
| 2017-01-03 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | +44,718 | -$39.0K | EDGAR |
| 2016-12-01 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | +190 | $1.6K | EDGAR |
| 2016-11-07 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-02 | Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Mixed | +196 | $1.6K | EDGAR |
| 2016-10-04 | Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Mixed | +148 | $1.6K | EDGAR |
| 2016-09-01 | Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Mixed | +137 | $1.6K | EDGAR |
| 2016-08-01 | Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Mixed | +190 | $1.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.